Enovis

Enovis is a publicly traded medical technology company whose principal focus is orthopedics. The company develops and commercializes products intended to support musculoskeletal care, including orthopedic implants, surgical technologies, trauma-related devices, spine products, and rehabilitation solutions. It is headquartered in Dallas, Texas, and trades on the New York Stock Exchange under the symbol ENOV. The company’s present identity is the result of a substantial portfolio transformation. It was established in 1995 by brothers Mitchell and Steven Rales as Colfax Corporation, initially as an industrial manufacturer and investment platform. In its early period, Colfax expanded through the acquisition of IMO, a diversified industrial business whose operations included power-transmission and fluid-handling activities. Colfax subsequently built a broader industrial portfolio through acquisitions, including Charter International in 2012. Charter brought the ESAB welding and cutting business and Howden, a manufacturer of air- and gas-handling equipment, into the group. During the 2010s, Colfax began reshaping that portfolio. It sold its original fluid-handling platform to Circor International in 2017 and acquired DJO Global from Blackstone in 2018. DJO was the transaction that established a major medical-technology platform within Colfax and gave the company exposure to orthopedic devices, rehabilitation, and related clinical markets. Colfax later agreed to sell Howden Turbo, further reducing its industrial exposure. In 2021, Colfax announced a plan to separate its ESAB industrial business and pursue a more concentrated medical-technology strategy. The separation was completed in April 2022. ESAB became an independent public company, while Colfax changed its name to Enovis. The renaming marked the completion of the company’s transition from a diversified industrial group into a focused medical technology business. Enovis has continued that strategy through acquisitions. In September 2023, it announced an agreement to acquire LimaCorporate, an Italian medical-device company headquartered in Villanova di San Daniele del Friuli, for approximately €800 million. The acquisition was reported as completed on January 3, 2024. LimaCorporate expanded Enovis’s orthopedic portfolio and strengthened its position in reconstructive and implant-based care. The company’s business is organized around technologies and products used by orthopedic surgeons, hospitals, clinicians, and rehabilitation professionals. Its portfolio includes joint-replacement systems, trauma and fixation products, spine-related technologies, surgical equipment, and rehabilitation products. Enovis presents itself as an innovation-oriented medical technology company seeking to improve patient outcomes and clinical workflows. Reference material describes a global operating footprint of more than 8,000 employees across approximately 30 sites, although the company’s precise current workforce and site count may change over time. Enovis is a medical technology company headquartered in Dallas, Texas. The business originated in 1995 when brothers Steven Rales and Mitchell Rales founded Colfax Corporation in Richmond, Virginia. Although Colfax first developed as an industrial holding company, its long-term corporate strategy evolved through acquisitions, divestitures, and portfolio restructuring into a focused medical technology enterprise. Colfax's early operating history was associated with fluid handling, power transmission, and other industrial equipment. In 1997, the company acquired approximately 93 percent of IMO's common stock through a tender offer. IMO had been a diversified industrial manufacturer whose businesses included Boston Gear, IMO Pump, Morse Controls, Gems Sensors, and Roltra Morse. Following the transaction, Gems Sensors and Roltra Morse were divested, leaving a narrower focus on power transmission and fluid-handling activities. A major expansion took place in January 2012, when Colfax completed its acquisition of Charter International for approximately $2.4 billion. Charter was the parent of ESAB, a welding and cutting business, and Howden, a manufacturer of air- and gas-handling equipment. The transaction substantially enlarged Colfax's international industrial platform. From 2012 through 2019, Colfax completed more than 25 acquisitions intended to develop three principal business areas: fluid handling, fabrication technologies through ESAB, and air and gas handling through Howden. The company subsequently began dismantling and redirecting that industrial portfolio. In December 2017, Colfax sold its original fluid-handling platform to Circor International in a transaction involving cash and stock with estimated aggregate consideration of approximately $860 million. In November 2018, it entered medical technology by acquiring DJO Global from The Blackstone Group for approximately $3.15 billion. DJO provided a platform in orthopedic and rehabilitation products and became central to Colfax's subsequent strategic repositioning. Colfax also agreed in 2019 to sell Howden Turbo to KPS Capital Partners for approximately $1.8 billion. In March 2021, the company announced plans to separate ESAB through a tax-efficient spin-off and to pursue a more concentrated medical technologies strategy. The separation was completed in April 2022. ESAB became an independent public company, while Colfax changed its name to Enovis. The rebranding represented the completion of a multi-year transformation from a diversified industrial company into a medical technology business. Enovis's present identity is therefore the result of both organic development and portfolio transactions. Its operations are centered on orthopedic products, surgical technologies, rehabilitation, and related medical-device activities, with business operations and sites across international markets. The company is publicly traded on the New York Stock Exchange under the symbol ENOV. In September 2023, Enovis announced an agreement to acquire LimaCorporate, an Italian medical-device company headquartered in Villanova di San Daniele del Friuli. The acquisition, valued at approximately €800 million, was reported as completed on January 3, 2024. The transaction further expanded Enovis's orthopedic medical-device portfolio and international reach. Enovis is a publicly traded medical technology company headquartered in Dallas, Texas, and listed on the New York Stock Exchange under the symbol ENOV. Its principal focus is orthopedics: it develops and commercializes orthopedic implants, joint-replacement systems, trauma and fixation devices, spine technologies, surgical equipment, and rehabilitation solutions for orthopedic surgeons, hospitals, clinicians, and rehabilitation professionals. The company originated in 1995, when brothers Mitchell and Steven Rales founded Colfax Corporation in Richmond, Virginia, as an industrial manufacturer and acquisition platform. In August 1997, Colfax acquired approximately 93 percent of IMO's common stock through a public tender offer; IMO was a diversified industrial manufacturer with reported annual revenue of $469 million and five business units (Boston Gear, IMO Pump, Morse Controls, Gems Sensors, and Roltra Morse). Around the completion of the tender offer, Colfax divested Gems Sensors and Roltra Morse, narrowing the platform toward power transmission and fluid handling. Colfax completed its initial public offering in May 2008 as a fluid-handling company. Colfax expanded substantially through acquisitions. In January 2012, it completed the approximately $2.4 billion acquisition of Charter International, parent of ESAB (welding and cutting) and Howden (air- and gas-handling equipment). From 2012 through 2019, Colfax completed more than 25 acquisitions, developing three principal industrial platforms: fluid handling, fabrication technologies through ESAB, and air and gas handling through Howden. The group then began a deliberate portfolio shift. In December 2017, it sold its original fluid-handling platform to Circor International in a cash-and-stock transaction with estimated aggregate consideration of approximately $860 million. In November 2018, Colfax acquired DJO Global from The Blackstone Group for approximately $3.15 billion, establishing a major medical-technology platform with exposure to orthopedic devices, rehabilitation, and related clinical markets. In May 2019, KPS Capital Partners agreed to acquire Howden Turbo from Colfax for approximately $1.8 billion, continuing the reduction of industrial assets. In March 2021, Colfax announced a plan to spin off ESAB in a tax-efficient transaction and pursue a focused medical technologies strategy. The separation was completed in April 2022: ESAB became an independent public company, and Colfax changed its name to Enovis, completing its transition from a diversified industrial group into a focused medical technology business. Enovis continued to expand through acquisitions. In September 2023, it announced a definitive agreement to acquire LimaCorporate, headquartered in Villanova di San Daniele del Friuli, Italy, for approximately €800 million. The purchase was reported as completed on January 3, 2024, adding an established orthopedic implant business and reinforcing Enovis's focus on reconstructive and musculoskeletal care. Reference material describes a global operating footprint of more than 8,000 employees across about 30 sites, though current figures may change over time.

Enovis traces its origins to Colfax Corporation, which was founded in 1995 in Richmond, Virginia, by brothers Mitchell Rales and Steven Rales. Colfax began as an industrial company rather than a medical-device specialist. In August 1997, it acquired approximately 93 percent of IMO’s common stock through a public tender offer. IMO was a diversified industrial manufacturer with reported annual revenue of $469 million at the time and five business units: Boston Gear, IMO Pump, Morse Controls, Gems Sensors, and Roltra Morse. Around the completion of the tender offer, Colfax divested the Gems Sensors and Roltra Morse businesses, narrowing the acquired platform toward power transmission and fluid handling. Colfax expanded substantially during the following decade. In January 2012, it completed the acquisition of Charter International, the parent company of ESAB and Howden, for approximately $2.4 billion. ESAB operated in welding and cutting, while Howden supplied air- and gas-handling products. From 2012 through 2019, Colfax completed more than 25 acquisitions as it developed three principal industrial platforms: fluid handling, fabrication technologies through ESAB, and air and gas handling through Howden. The group began a deliberate portfolio shift in the late 2010s. In December 2017, it sold its original fluid-handling platform to Circor International in a cash-and-stock transaction with estimated aggregate consideration of approximately $860 million. In November 2018, Colfax acquired DJO Global from The Blackstone Group for approximately $3.15 billion. DJO provided a route into medical devices and gave Colfax exposure to orthopedic products, rehabilitation, and related healthcare markets. In May 2019, KPS Capital Partners announced an agreement to acquire Howden Turbo from Colfax for approximately $1.8 billion, continuing the reduction of the company’s industrial assets. In March 2021, Colfax announced that it intended to spin off ESAB in a tax-efficient transaction and pursue a more focused medical technologies strategy. The separation was completed in April 2022. ESAB became an independent public company, and Colfax changed its corporate name to Enovis. The transaction completed a multi-year transformation that had included the divestiture of fluid handling, the disposal of air- and gas-handling assets, and the acquisition of DJO Global. It also marked the end of Colfax’s identity as a primarily industrial company. Enovis continued to expand its medical-technology platform through acquisitions. In September 2023, it announced a definitive agreement to acquire LimaCorporate, headquartered in Villanova di San Daniele del Friuli, Italy, for approximately €800 million. The purchase was reported as completed on January 3, 2024. LimaCorporate added an established orthopedic implant business and reinforced Enovis’s focus on reconstructive and musculoskeletal care. Today, Enovis is described as a global medical technology company focused on orthopedics. Its activities encompass implants, surgical technologies, trauma and fixation products, spine-related devices, and rehabilitation solutions. The company is headquartered in Dallas, Texas, and is listed on the New York Stock Exchange under ENOV. Reference material states that it has more than 8,000 employees operating across about 30 sites worldwide. Because the company’s portfolio and organizational structure may continue to change through acquisitions and divestitures, current product boundaries and operating statistics should be checked against its latest corporate filings. Enovis began in 1995 as Colfax Corporation, founded in Richmond, Virginia, by brothers Steven Rales and Mitchell Rales. The early company operated as an industrial acquisition and management platform rather than as a consumer-facing product brand. Its first major transaction described in the company's history was the 1997 acquisition of approximately 93 percent of IMO's common stock. IMO had five principal business units, including Boston Gear, IMO Pump, Morse Controls, Gems Sensors, and Roltra Morse. Colfax and IMO narrowed the resulting portfolio by divesting Gems Sensors and Roltra Morse, emphasizing power transmission and fluid handling. The company's industrial scale increased substantially through the 2012 acquisition of Charter International, the parent company of ESAB and Howden. Completed in January 2012 for approximately $2.4 billion, the deal gave Colfax substantial businesses in welding and cutting, air handling, and gas-handling equipment. Colfax then used acquisitions to develop three operating platforms: fluid handling, fabrication technologies, and air and gas handling. More than 25 acquisitions were completed between 2012 and 2019, according to the company's historical account. After building this diversified industrial portfolio, Colfax began to simplify it. In December 2017, the company sold its original fluid-handling platform to Circor International for a combination of cash and stock. The estimated aggregate consideration was approximately $860 million. In November 2018, Colfax acquired DJO Global from The Blackstone Group for approximately $3.15 billion. DJO's orthopedic and rehabilitation activities provided the foundation for the company's move into medical technology. Colfax continued to exit industrial activities in 2019. KPS Capital Partners agreed to acquire Howden Turbo from Colfax for approximately $1.8 billion. In March 2021, Colfax disclosed a plan to separate ESAB and pursue a focused medical technology strategy. The ESAB separation was completed in April 2022, creating an independent public company. After the spin-off, the remaining company adopted the name Enovis, signaling the completion of its transition from a broadly diversified industrial group to a medical technology company. The corporate transformation also changed the company's geographic and organizational profile. Colfax had gone public in May 2008 as a fluid-handling company, and its headquarters were later moved to Annapolis Junction, Maryland. Under the Enovis identity, headquarters are in Dallas, Texas, and the company operates through an international network of sites with a focus on orthopedic and related healthcare technologies. Enovis continued expanding through medical-device acquisitions. In September 2023, it announced an agreement to acquire LimaCorporate, headquartered in Villanova di San Daniele del Friuli, Italy, for approximately €800 million. The transaction was reported as completed on January 3, 2024. LimaCorporate's inclusion strengthened Enovis's orthopedic reconstruction and implant capabilities and continued the acquisition-led development of the medical technology portfolio. Enovis is listed on the New York Stock Exchange under the ticker ENOV.

• 2024

  LimaCorporate acquisition completed

  [1]Enovisen.wikipedia.org

  The LimaCorporate transaction was reported as completed on January 3, 2024.

• 2023

  LimaCorporate acquisition announced

  [1]Enovisen.wikipedia.org

  Enovis announced a definitive agreement to acquire Italian orthopedic-device company LimaCorporate for approximately €800 million.

• 2022

  ESAB spin-off and Enovis name adopted

  [1]Enovisen.wikipedia.org

  The ESAB separation was completed in April 2022; ESAB became an independent public company and Colfax was renamed Enovis.

• 2021

  Medical-technology transformation announced

  [1]Enovisen.wikipedia.org

  Colfax announced plans to spin off ESAB in a tax-efficient transaction and pursue a focused medical technologies strategy.

• 2021

  Medical technology refocusing plan

  [1]Enovisen.wikipedia.org

  Colfax announced plans to spin off ESAB and concentrate the remaining company on medical technologies.

• 2019

  Howden Turbo sale agreement

  [1]Enovisen.wikipedia.org

  KPS Capital Partners agreed to acquire Howden Turbo from Colfax for approximately $1.8 billion.

• 2018

  DJO Global acquired

  [1]Enovisen.wikipedia.org

  Colfax acquired DJO Global from The Blackstone Group for approximately $3.15 billion, establishing a substantial medical-device platform within the group.

• 2017

  Fluid-handling platform sold

  [1]Enovisen.wikipedia.org

  Colfax sold its original fluid-handling platform to Circor International in a cash-and-stock transaction with estimated aggregate consideration of approximately $860 million.

• 2012

  Charter International acquired

  [1]Enovisen.wikipedia.org

  Colfax completed its approximately $2.4 billion acquisition of Charter International, whose businesses included ESAB and Howden.

• 2008

  Initial public offering

  [1]Enovisen.wikipedia.org

  Colfax completed its initial public offering in May 2008 as a fluid-handling company.

Showing the 10 most recent.

A focused medical technology company positioned around orthopedic innovation, surgical care, implants, and rehabilitation, with an emphasis on clinical applications and patient outcomes. A global medical technology company focused on orthopedic care, surgical solutions, rehabilitation, and technologies intended to improve patient mobility and recovery. Historically, the company was positioned as a diversified industrial manufacturer under the Colfax name, but its current strategy is centered on healthcare and orthopedic medical devices.

• Orthopedic devices · 2024

  LimaCorporate orthopedic implants

  Enovis’s orthopedic implant activities include products used in reconstructive and joint-related procedures. The portfolio expanded materially through the company’s medical-device acquisitions, including DJO Global and LimaCorporate. These products are intended for use by orthopedic specialists in surgical treatment of musculoskeletal conditions. LimaCorporate became part of Enovis following the acquisition reported as completed in January 2024. Its inclusion expanded Enovis's orthopedic reconstruction and implant capabilities and strengthened the company's international medical-device portfolio.

• Orthopedic implants

  Joint-replacement systems

  Joint-replacement systems are a core part of Enovis's orthopedic positioning. They are designed for reconstructive procedures in which damaged or diseased joints are replaced or supported with implant components. Specific system names, indications, and geographic availability vary across the company's portfolio.

• Trauma orthopedics

  Trauma and fixation devices

  The trauma portfolio consists of devices used to stabilize and repair musculoskeletal injuries, including fracture-related applications. These products support orthopedic surgical procedures and form part of Enovis's broader focus on trauma, reconstruction, and patient recovery.

• Rehabilitation technology

  Rehabilitation solutions

  Enovis offers rehabilitation-oriented products associated with recovery, mobility, bracing, and musculoskeletal support. The category reflects the company's heritage in DJO Global and its stated interest in serving patients across treatment and recovery rather than only at the surgical stage.

• Spine devices

  Spine technologies

  Spine-related technologies form part of Enovis's orthopedic medical-device scope. They are intended for clinical applications involving spinal treatment and surgery. The available reference material does not identify individual product families or launch dates.

• Surgical technology

  Surgical equipment

  Enovis's surgical technology offering includes equipment and related solutions used by healthcare professionals in orthopedic procedures. The category complements the company's implants and fixation products by addressing procedural needs in the operating environment.

• Orthopedic and rehabilitation medical devices · 2018

  DJO orthopedic and rehabilitation portfolio

  The DJO business formed the principal foundation of Colfax's entry into medical technology. Its portfolio is associated with orthopedic care, rehabilitation, recovery, supports, and related products intended for patients and clinicians. The acquisition gave Colfax an established healthcare platform and supported the later transition to the Enovis identity.

• Orthopedic medical technology · 2022

  Enovis orthopedic technologies

  Enovis's current product scope centers on orthopedic technologies, including products and systems used in surgical care, joint reconstruction, extremity treatment, sports medicine, and rehabilitation. The company presents these activities as part of a broader effort to improve patient mobility and recovery.

• 2023

  Agreement to acquire LimaCorporateM&A

  Background

  Enovis continued building its orthopedic medical-device portfolio through international acquisitions.

  Action taken

  Enovis agreed to acquire LimaCorporate, an Italian medical-device company headquartered in Villanova di San Daniele del Friuli.

  Aftermath

  The transaction was reported as completed on January 3, 2024, expanding Enovis's orthopedic reconstruction and implant activities.

  Announced acquisition consideration. Approximately €800 million (September 2023)

  Source

• 2021

  Decision to separate ESABStrategy

  Background

  Colfax had accumulated a medical-device platform while still owning major industrial businesses, and it announced a plan to focus the remaining company on medical technologies.

  Action taken

  The company announced a tax-efficient spin-off of ESAB and a concentrated medical technologies strategy.

  Aftermath

  The separation was completed in April 2022, ESAB became independent, and Colfax changed its name to Enovis.

  Source

• 2021

  Separate ESAB and focus on medical technologiesStrategy

  Background

  After divesting fluid handling and agreeing to exit air and gas handling, Colfax planned to complete its transformation into a medical technology company.

  Action taken

  The company announced a tax-efficient spin-off of ESAB and a focused medical technologies strategy for the remaining business.

  Aftermath

  The spin-off was completed in April 2022, ESAB became independent, and Colfax adopted the Enovis name.

  Source

• 2018

  DJO Global acquisitionM&A

  Background

  Colfax sought a major entry into medical technology as it began moving away from a purely industrial portfolio.

  Action taken

  Colfax acquired DJO Global from The Blackstone Group for approximately $3.15 billion.

  Aftermath

  DJO became the central platform for the company's orthopedic and rehabilitation activities and supported the later Enovis rebrand.

  Acquisition price. $3.15 billion (November 2018)

  Source

• 2017

  Sale of original fluid-handling platformM&A

  Background

  Colfax began reducing the industrial portfolio that had defined its earlier business model.

  Action taken

  The company sold its original fluid-handling platform to Circor International for cash and stock.

  Aftermath

  The divestiture was part of the longer transition toward medical technologies. The divestiture reduced Colfax's exposure to its original operating area and preceded the company's expansion into medical technology.

  Estimated aggregate consideration. $860 million (December 2017)

  Source

• 2012

  Charter International acquisitionM&A

  Background

  Colfax aimed to broaden its industrial businesses through a large-scale acquisition. Colfax sought to expand its industrial platform beyond its earlier fluid-handling and power-transmission activities.

  Action taken

  The company completed the acquisition of Charter International, parent of ESAB and Howden, for approximately $2.4 billion.

  Aftermath

  The transaction created the foundation for Colfax's fabrication-technologies and air-and-gas-handling businesses and was followed by numerous additional industrial acquisitions.

  Acquisition consideration. $2.4 billion (January 2012)

  Source

• 1997

  IMO tender offer and portfolio narrowingM&A

  Background

  Colfax sought to expand its industrial platform through the acquisition of IMO, which operated across several industrial businesses.

  Action taken

  Colfax acquired approximately 93 percent of IMO’s common stock and divested the Gems Sensors and Roltra Morse units around the transaction’s completion.

  Aftermath

  The transaction concentrated the acquired business more closely on power transmission and fluid handling.

  IMO annual revenue at the time of acquisition. $469.0 million (1997)

  Source

• 2024

  LimaCorporate acquisition completed[1]Enovisen.wikipedia.org

  M&A

  The acquisition of LimaCorporate was reported as completed on January 3, 2024, extending Enovis’s orthopedic medical-device portfolio.

• 2023

  Enovis agrees to acquire LimaCorporate[1]Enovisen.wikipedia.org

  M&A

  Enovis announced a definitive agreement to acquire LimaCorporate, an Italian medical-device company, for approximately €800 million.

• 2022

  ESAB separation completed and Colfax renamed Enovis[1]Enovisen.wikipedia.org

  Leadership change

  The ESAB spin-off was completed in April 2022. Following the transaction, ESAB became an independent public company and Colfax adopted the Enovis name.

• 2021

  Colfax announces ESAB separation and medical technology strategy[1]Enovisen.wikipedia.org

  M&A

  Colfax announced plans to spin off its ESAB fabrication-technology business and concentrate the remaining company on medical technologies.

• 2019

  Colfax agrees to sell Howden Turbo[1]Enovisen.wikipedia.org

  M&A

  KPS Capital Partners announced an agreement to acquire Howden Turbo from Colfax for approximately $1.8 billion, continuing Colfax's divestiture of industrial assets.

• 2018

  Colfax announces acquisition of DJO Global[1]Enovisen.wikipedia.org

  M&A

  Colfax announced an agreement to acquire DJO Global from The Blackstone Group for approximately $3.15 billion, marking a major expansion into medical technology and orthopedic products.

1. 1Enovisen.wikipedia.org
2. 2Enovis official websiteenovis.com
3. 3http://www.colfaxcorp.comcolfaxcorp.com